ArticleClinical epigenetics2026
Smoking behaviour, altered DNA methylation, and heart failure risk: evidence from a prospective cohort and epigenetic Mendelian randomization study.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo date, there is still a lack of studies focusing on the interactions between tobacco smoking, epigenetic modifications, and heart failure (HF) risk.
methodsWe first performed a prospective cohort study in the UK Biobank to assess the causal relationship between smoking behaviours and HF incidence. Subsequently, we applied two-sample Mendelian Randomization (MR) and epigenetic MR to further investigate the causal effects of smoking behaviours and related DNA methylation on HF, including its subtypes: heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
resultsIn the UK Biobank cohort, former, ever, and current smoking were all associated with a higher risk of HF, with a clear dose-response relationship observed for pack-years of smoking. Additionally, earlier smoking cessation was linked to a lower risk of HF. Two-sample MR validated these observational findings and further identified the harmful effects of smoking behaviours on both HFpEF and HFrEF. In the epigenetic MR analysis, we found that DNA methylation alteration at cg15234271 [HPN] was associated with a reduced risk of HF, whereas cg16071219 [LPAR6], cg19593285 [E2F1], and cg01305745 [VKORC1] were linked to an elevated risk. For HF subtypes, cg26161820 [PPP1R1B] and cg26716839 [UNC119B] were associated with a lowered risk of HFrEF, while cg08548559 [PIK3IP1] was linked to an increased risk of HFpEF.
conclusionOur study demonstrates associations between smoking behaviours, related DNA methylation, and HF incidence, offering novel insights into the pathogenesis of HF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.